In vivo tumor characterization using both MR and optical contrast agents with a hybrid MRI-DOT system

Dynamic contrast enhanced MRI (DCE-MRI) has been proven to be the most sensitive modality in detecting breast lesions. Currently available MR contrast agent, Gd-DTPA, is a low molecular weight extracellular agent and can diffuse freely from the vascular space into interstitial space. Due to this reason, DCE-MRI has low sensitivity in differentiating benign and malignant tumors. Meanwhile, diffuse optical tomography (DOT) can be used to provide enhancement kinetics of an FDA approved optical contrast agent, ICG, which behaves like a large molecular weight optical agent due to its binding to albumin. The enhancement kinetics of ICG may have a potential to distinguish between the malignant and benign tumors and hence improve the specificity. Our group has developed a high speed hybrid MRI-DOT system. The DOT is a fully automated, MR-compatible, multi-frequency and multi-spectral imaging system. Fischer-344 rats bearing subcutaneous R3230 tumor are injected simultaneously with Gd-DTPA (0.1nmol/kg) and IC-Green (2.5mg/kg). The enhancement kinetics of both contrast agents are recorded simultaneously with this hybrid MRI-DOT system and evaluated for different tumors.

[1]  Soren D. Konecky,et al.  Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. , 2009, Journal of biomedical optics.

[2]  J. Ripoll,et al.  In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green. , 2003, Medical physics.

[3]  B. Tromberg,et al.  Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy , 2007, Proceedings of the National Academy of Sciences.

[4]  V. Ntziachristos,et al.  Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Anthony J. Durkin,et al.  In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. , 2003, Applied optics.

[6]  Dirk Grosenick,et al.  Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions. , 2009, Optics express.

[7]  L. O. Svaasand,et al.  Boundary conditions for the diffusion equation in radiative transfer. , 1994, Journal of the Optical Society of America. A, Optics, image science, and vision.

[8]  B. Pogue,et al.  Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. , 2009, Radiology.

[9]  M. Huang,et al.  Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. , 2003, Neoplasia.

[10]  C. Bell,et al.  BIOCHEMICAL AND MORPHOLOGIC PROPERTIES OF A NEW LACTATING MAMMARY TUMOR LINE IN THE RAT. , 1965, Cancer research.

[11]  Hamid Dehghani,et al.  Structural information within regularization matrices improves near infrared diffuse optical tomography. , 2007, Optics express.

[12]  Ozlem Birgul,et al.  Design and implementation of a multifrequency near-infrared diffuse optical tomography system. , 2006, Journal of biomedical optics.

[13]  L. Turnbull.  Dynamic contrast‐enhanced MRI in the diagnosis and management of breast cancer , 2009, NMR in biomedicine.